Metrics as of 10/16/2026, 08:31 AM (Berlin time), refresh in progress.
NanoViricides Stock
NanoViricides, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Anil R. Diwan
- Employees
- 7
- Market cap
- $35 M
- IPO
- 26/10/2005
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and…
NanoViricides stock: price history
1D
+4.6%
1W
+4.6%
1M
+30.5%
6M
+18.1%
YTD
+21.2%
1Y
-4.9%
2Y
-8.7%
5Y
-71.9%
10Y
-95.8%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about NanoViricides
Analyst assessment of NanoViricides
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 07/05/2024
NanoViricides stock metrics
P/E
-3.32
P/B
0
EV/EBITDA
362,109.37
RETURN ON EQUITY
-0.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.0%
FLOAT SHARES
21,180,773
AVG. DAILY VOLUME (30D)
546,272
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about NanoViricides stock
What does NanoViricides do?
NanoViricides, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Anil R. Diwan, the company employs around 7 people.
The IPO was on 26/10/2005; the stock trades on AMEX under the ticker NNVC.
What do analysts say about NanoViricides stock?
1 analysts rate the stock, the consensus is Buy (as of 07/05/2024).
This is an external assessment, not a statement by Market Jury.
When does NanoViricides report next?
Around past earnings, price swings were roughly 5% stronger than usual.
Does NanoViricides pay a dividend?
No, NanoViricides currently does not pay a dividend.
Which stocks are comparable to NanoViricides?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get NanoViricides stock analyzed?
Clicking "Analyze stock" lets five strategies assess NanoViricides against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.